The KCNJ9 antibody is a research tool designed to detect and study the KCNJ9 protein, also known as G protein-activated inward rectifier potassium channel 3 (GIRK3). KCNJ9 is a member of the inwardly rectifying potassium channel (Kir) family, specifically the Kir3 subfamily, which plays a critical role in regulating cellular excitability and signaling in various tissues, including the brain, heart, and endocrine systems. These channels are activated by G protein-coupled receptors (GPCRs) and contribute to slow inhibitory neurotransmission, heart rate modulation, and hormone secretion.
KCNJ9 has been implicated in neurological disorders, cardiovascular diseases, and cancer. For instance, altered expression or function of GIRK3 channels is linked to conditions like epilepsy, Parkinson’s disease, and addiction-related behaviors. In oncology, KCNJ9 may influence tumor progression through its role in cell proliferation and apoptosis.
Antibodies targeting KCNJ9 enable researchers to investigate its expression patterns, subcellular localization, and interactions in both normal and pathological states. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Validating these antibodies for specificity and sensitivity is crucial, as cross-reactivity with other Kir family members can occur. Recent studies employing KCNJ9 antibodies have provided insights into its tissue-specific roles and potential as a therapeutic target, particularly in neurological and oncological research.